Day: August 20, 2025

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Written by Customer Service on August 20, 2025. Posted in Earnings Releases And Operating Results.

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here. Second Quarter 2025 Business Update HighlightsOn track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1. Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch. Strong support from leading...

Rekordhøye andrekvartalsvolumer og -inntekter for Mowi

Written by Customer Service on August 20, 2025. Posted in Earnings Releases And Operating Results.

(Bergen, 20. august 2025) Mowi rapporterte inntekter på 1,39 milliarder euro (16,29 milliarder kroner) og et operasjonelt driftsresultat på 189 millioner euro (2,20 milliarder kroner) i andre kvartal. Andre kvartal endte med rekordhøye inntekter for Mowi for denne delen av året, som følge av sterk biologisk og operasjonell drift, rekordhøye volumer og lavere kostnader. – 2025 har vært et godt år med meget god drift og sterk vekst så langt for havbruksvirksomheten, sier konsernsjef i Mowi, Ivan Vindheim. Mowi slaktet rekordhøye 133 000 tonn i andre kvartal, som er en vekst på hele 21% sammenlignet med i fjor. Mowi øker derfor volumguidingen for 2025 fra 530 000 tonn til 545 000 tonn, som tilsvarer en vekst på 9% fra 2024. – Det er gledelig å se at vi leverer på vekststrategien vår, og med nylig inngått avtale om økt eierandel i Nova Sea...

Seasonally record-high volumes and revenues for Mowi in Q2

Written by Customer Service on August 20, 2025. Posted in Earnings Releases And Operating Results.

(Bergen, 20 August 2025) Mowi generated operating revenues of EUR 1.39 billion in the second quarter which translated into an operational profit of EUR 189 million. The second quarter of 2025 ended with record-high revenues for Mowi, on strong biological and operational performance, all-time high volumes and decreasing cost. “2025 has so far been a good year for the Farming division with very good operations and strong growth,” said Mowi CEO, Ivan Vindheim. Mowi harvested a record 133,000 tonnes in the second quarter, representing growth of 21% compared with last year. The company has consequently increased its volume guidance for 2025 to 545,000 tonnes on strong seawater growth, equivalent to annual growth of 9% from 2024. “It is satisfying to see that we are delivering on our strategy. With the recently concluded agreement to increase...

Lerøy Seafood Group ASA: Solid operations across all segments, strong earnings in VAP S&D and Wild Catch

Written by Customer Service on August 20, 2025. Posted in Earnings Releases And Operating Results.

“We delivered solid operations across all segments in the second quarter, resulting in an operational EBIT of NOK 680 million in the quarter. The quarter clearly illustrates the robustness of our business model with a fully integrated value chain in a diversified seafood company,” says CEO of Lerøy Seafood Group ASA (LSG), Henning Beltestad. FARMING – STRONG BIOLOGICAL PERFORMANCE BUT LOW PRICES FOR SALMON AND TROUT. Operational EBIT in the second quarter of 2025 ended at NOK 256 million in the Farming segment. “LSG achieved its highest net growth ever for a second quarter. Survival rates are high, the share of superior quality is high, and the average harvest weight has increased, while cost per kg is declining. This is due to a very strong biological performance. We see a more challenging start to the third quarter,...

Blue Moon Metals Secures up to US$140 Million Project Finance Package from Hartree/Oaktree to Advance Flagship Nussir Project in Norway

Written by Customer Service on August 20, 2025. Posted in Public Companies.

TORONTO, Ontario, Aug. 19, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company“) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce that it has entered into a memorandum of understanding with Hartree Partners, LP (“Hartree“) and funds managed by Oaktree Capital Management, L.P. (“Oaktree“, together with Hartree, the “Lenders“, and each a “Lender“) which consists of a previously agreed to bridge loan (the “Bridge Loan“) with Nussir ASA, a 93.55% owned subsidiary of the Company, as borrower, and Keystone Mines Inc., Blue Moon Norway AS and Repparfjord Eiendom AS, each a wholly owned subsidiary of the Company, as guarantors, as well as terms related a project financing package (the “Project Finance Package” and together...

High Arctic Announces the Executive Management Changes

Written by Customer Service on August 20, 2025. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Aug. 19, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) announces the resignation of Mr. Mike Maguire as Chief Executive officer and the appointment of Mr. Lonn Bate as Interim Chief Executive Officer, effective today, August 19, 2025. Mr. Bate has been Chief Financial Officer of the Corporation since July 1, 2024 and prior to that he has been involved with the Corporation in a consulting capacity from March 2023. In addition, the Corporation is pleased to announce the appointment of Mr. Jay Bachman as Interim Chief Financial Officer, also effective August 19, 2025, subject...

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Written by Customer Service on August 20, 2025. Posted in Public Companies.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. The last patient was enrolled on August 18, 2025. This Phase III trial is a blinded, randomized, controlled study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression. The study will evaluate the efficacy and safety of TAGRISSO® in combination with ORPATHYS® comparing to TAGRISSO® alone, a standard-of-care...

Day: August 20, 2025

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Rekordhøye andrekvartalsvolumer og -inntekter for Mowi

Seasonally record-high volumes and revenues for Mowi in Q2

Lerøy Seafood Group ASA: Solid operations across all segments, strong earnings in VAP S&D and Wild Catch

Blue Moon Metals Secures up to US$140 Million Project Finance Package from Hartree/Oaktree to Advance Flagship Nussir Project in Norway

High Arctic Announces the Executive Management Changes

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals